PHARMVILLE_LIMITED - Accounts


Company Registration No. 07167184 (England and Wales)
PHARMVILLE LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
PAGES FOR FILING WITH REGISTRAR
PHARMVILLE LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
PHARMVILLE LIMITED
BALANCE SHEET
AS AT
30 APRIL 2019
30 April 2019
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Intangible assets
3
147,777
184,722
Tangible assets
4
10,205
9,020
157,982
193,742
Current assets
Stocks
18,145
28,160
Debtors
5
93,735
96,463
Cash at bank and in hand
11,295
10,544
123,175
135,167
Creditors: amounts falling due within one year
6
(210,174)
(198,287)
Net current liabilities
(86,999)
(63,120)
Total assets less current liabilities
70,983
130,622
Creditors: amounts falling due after more than one year
7
(70,878)
(130,333)
Net assets
105
289
Capital and reserves
Called up share capital
8
100
100
Profit and loss reserves
5
189
Total equity
105
289

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

PHARMVILLE LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2019
30 April 2019
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 26 January 2020
G  Avbulimen
Director
Company Registration No. 07167184
PHARMVILLE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
- 3 -
1
Accounting policies
Company information

Pharmville Limited is a private company limited by shares incorporated in England and Wales. The registered office is Lynwood House, 373-375 Station Road, Harrow, Middlesex, HA1 2AW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised in the period in which the services were supplied.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% reducing balance
Motor vehicles
20% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

PHARMVILLE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
1
Accounting policies
(Continued)
- 4 -
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.8
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

PHARMVILLE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
1
Accounting policies
(Continued)
- 5 -
1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 6 (2018 - 6).

PHARMVILLE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
- 6 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2018 and 30 April 2019
700,000
Amortisation and impairment
At 1 May 2018
515,278
Amortisation charged for the year
36,945
At 30 April 2019
552,223
Carrying amount
At 30 April 2019
147,777
At 30 April 2018
184,722
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2018
30,918
Additions
3,736
At 30 April 2019
34,654
Depreciation and impairment
At 1 May 2018
21,898
Depreciation charged in the year
2,551
At 30 April 2019
24,449
Carrying amount
At 30 April 2019
10,205
At 30 April 2018
9,020
5
Debtors
2019
2018
Amounts falling due within one year:
£
£
Trade debtors
65,562
69,277
Other debtors
28,173
27,186
93,735
96,463
PHARMVILLE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
- 7 -
6
Creditors: amounts falling due within one year
2019
2018
£
£
Bank loans and overdrafts
91,186
90,633
Trade creditors
110,461
91,847
Taxation and social security
(1,506)
3,509
Other creditors
10,033
12,298
210,174
198,287
7
Creditors: amounts falling due after more than one year
2019
2018
£
£
Bank loans and overdrafts
70,878
130,333
8
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
60 Ordinary A Shares of £1 each
60
60
20 Ordinary B Shares of £1 each
20
20
20 Ordinary C Shares of £1 each
20
20
100
100
9
Directors' transactions

Loans have been granted by the company to its directors as follows:

Description
% Rate
Opening balance
Amounts advanced
Interest charged
Amounts repaid
Closing balance
£
£
£
£
£
2.50
16,950
27,679
310
(29,150)
15,789
16,950
27,679
310
(29,150)
15,789

The brought forward loan of £16,950 was repaid on 30 November 2018. The carry forward loan of £15,789 was repaid within 9 months of the balance sheet date.

2019-04-302018-05-01false27 January 2020CCH SoftwareCCH Accounts Production 2019.301No description of principal activityG071671842018-05-012019-04-30071671842019-04-3007167184core:NetGoodwill2019-04-3007167184core:NetGoodwill2018-04-30071671842017-05-012018-04-30071671842018-04-3007167184core:OtherPropertyPlantEquipment2019-04-3007167184core:OtherPropertyPlantEquipment2018-04-3007167184core:CurrentFinancialInstrumentscore:WithinOneYear2019-04-3007167184core:CurrentFinancialInstrumentscore:WithinOneYear2018-04-3007167184core:CurrentFinancialInstruments2019-04-3007167184core:CurrentFinancialInstruments2018-04-3007167184core:Non-currentFinancialInstruments2019-04-3007167184core:Non-currentFinancialInstruments2018-04-3007167184core:ShareCapital2019-04-3007167184core:ShareCapital2018-04-3007167184core:RetainedEarningsAccumulatedLosses2019-04-3007167184core:RetainedEarningsAccumulatedLosses2018-04-3007167184core:ShareCapitalOrdinaryShares2019-04-3007167184core:ShareCapitalOrdinaryShares2018-04-3007167184bus:Director12018-05-012019-04-3007167184core:Goodwill2018-05-012019-04-3007167184core:FurnitureFittings2018-05-012019-04-3007167184core:MotorVehicles2018-05-012019-04-3007167184core:NetGoodwill2018-04-3007167184core:NetGoodwill2018-05-012019-04-3007167184core:OtherPropertyPlantEquipment2018-04-3007167184core:OtherPropertyPlantEquipment2018-05-012019-04-3007167184core:WithinOneYear2019-04-3007167184core:WithinOneYear2018-04-3007167184bus:PrivateLimitedCompanyLtd2018-05-012019-04-3007167184bus:SmallCompaniesRegimeForAccounts2018-05-012019-04-3007167184bus:FRS1022018-05-012019-04-3007167184bus:AuditExemptWithAccountantsReport2018-05-012019-04-3007167184bus:FullAccounts2018-05-012019-04-30xbrli:purexbrli:sharesiso4217:GBP